INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours
  • Phase Unknown Follicular lymphoma

Most Recent Events

  • 31 Jan 2017 Investigation in Follicular lymphoma in USA (unspecified route) before January 2017
  • 31 Jan 2017 Incyte Corporation plans a phase I trial for Follicular lymphoma (Combination therapy, Second-line therapy or greater) (NCT03039114)
  • 03 Dec 2016 Updated efficacy, pharmacokinetics and safety data from a phase I/II trial in B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top